Gain Therapeutics Reports Results From Single Ascending Dose Part Of Phase 1 Clinical Trial Of GT-02287, Novel GCase-Targeting Small Molecule Therapy For GBA1 Parkinson's Disease
Gain Therapeutics Reports Results From Single Ascending Dose Part Of Phase 1 Clinical Trial Of GT-02287, Novel GCase-Targeting Small Molecule Therapy For GBA1 Parkinson's Disease
Gain Therapeutics 報告了針對 GBA1 帕金森氏病的新型 GCase 靶向小分子療法 GT-02287 的 1 期臨床試驗的單一遞增劑量部分的結果
GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events. The good safety and tolerability profile and the appropriate range of plasma exposure levels achieved after oral administration further bolster GT-02287's best and first-in-class potential.
在最高計劃劑量水平之前，GT-02287 的耐受性通常良好，並且沒有嚴重的不良事件。良好的安全性和耐受性以及口服後達到的適當範圍的血漿暴露水平進一步增強了 GT-02287 的最佳和一流的潛力。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。